Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients

Hashimoto, Kenji; Engberg, Göran; Shimizu, Eiji; Nordin, Conny; Lindström, Leif H.; Iyo, Masaomi
January 2005
BMC Psychiatry;2005, Vol. 5, p6
Academic Journal
Background: Recent magnetic resonance spectroscopy (MRS) studies report that glutamine is altered in the brains of schizophrenic patients. There were also conflicting findings on glutamate in cerebrospinal fluid (CSF) of schizophrenic patients, and absent for glutamine. This study aims to clarify the question of glutamine and glutamate in CSF of first episode and drug naive schizophrenic patients. Method: Levels of glutamine and glutamate in CSF of 25 first episode and drug-naive male schizophrenic patients and 17 age-matched male healthy controls were measured by a high performance liquid chromatography. Results: The ratio (126.1 (median), 117.7 ã 27.4 (mean ã S.D.)) of glutamine to glutamate in the CSF of patients was significantly (z = -3.29, p = 0.001) higher than that (81.01 (median), 89.1 ã 22.5 (mean ã S.D.)) of normal controls although each level of glutamine and glutamate in patients was not different from that of normal controls. Conclusion: Our data suggests that a disfunction in glutamate-glutamine cycle in the brain may play a role in the pathophysiology of schizophrenia.


Related Articles

  • Higher Levels of Glutamate in the Associative-Striatum of Subjects with Prodromal Symptoms of Schizophrenia and Patients with First-Episode Psychosis. Fuente-Sandoval, Camilo de la; León-Ortiz, Pablo; Favila, Rafael; Stephano, Sylvana; Mamo, David; Ramírez-Bermúdez, Jesús; Graff-Guerrero, Ariel // Neuropsychopharmacology;Aug2011, Vol. 36 Issue 9, p1781 

    The glutamatergic and dopaminergic systems are thought to be involved in the pathophysiology of schizophrenia. Their interaction has been widely documented and may have a role in the neurobiological basis of the disease. The aim of this study was to compare, using proton magnetic resonance...

  • Glutamate Level Decreases Significantly in Patients With Secondary Progressive MS. Greb, Erik // Neurology Reviews;Jan2014, Vol. 22 Issue 1, p21 

    A conference paper about decline in glutamate level in secondary progressive multiple sclerosis (MS) patients discussed at the 29th Congress of the European Committee for Treatment and Research in MS (FCTRIMS) is presented. Topics discussed include glutamate and glutamine may result to a loss of...

  • A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity. Goodall, E.; Oxtoby, C.; Richards, R.; Watkinson, G.; Brown, D.; Silvestone, T.; Silverstone, T // British Journal of Psychiatry;Aug88, Vol. 153, p208 

    Twenty-nine overweight schizophrenic patients maintained on depot neuroleptic injections who wished to lose weight took part in a double-blind, placebo-controlled trial of 30 mg D-fenfluramine. All subjects received dietary advice. Sixteen patients completed the 12-week trial. Rate of weight...

  • Drug prescribing for schizophrenic out-patients on depot injections. Repeat surveys over 18 years. Johnson, D.A.W; Wright, N.F; Johnson, D A // British Journal of Psychiatry;Jun90, Vol. 156, p827 

    Serial surveys of the prescribing practices of psychiatrists for schizophrenic out-patients over 1970-88 showed important changes. During the interval 1970-83, polypharmacy and the use of multiple neuroleptics were reduced. The total dose of neuroleptics prescribed fell and the proportion...

  • Brainstem involvement in subacute sclerosing panencephalitis.  // Turkish Journal of Pediatrics;Sep/Oct2010, Vol. 52 Issue 5, p542 

    No abstract available.

  • Olanzapine Increases Grey and White Matter Volumes in the Caudate Nucleus of Patients with Schizophrenia. Okugawa, Gaku; Nobuhara, Kenji; Takase, Katsunori; Saito, Yukiko; Yoshimura, Masafumi; Kinoshita, Toshihiko // Neuropsychobiology;2007, Vol. 55 Issue 1, p43 

    There are inconsistent reports regarding the caudate nucleus volume in patients with schizophrenia compared with healthy subjects. The reason for this is that neuroleptic medication may affect the volume of the caudate nucleus in schizophrenic patients. To clarify which antipsychotic medication...

  • Regional Decoupling of N-acetyl-aspartate and Glutamate in Schizophrenia. Kraguljac, Nina V; Reid, Meredith A; White, David M; den Hollander, Jan; Lahti, Adrienne C // Neuropsychopharmacology;Nov2012, Vol. 37 Issue 12, p2635 

    Proton magnetic resonance spectroscopy (1H-MRS) allows the non-invasive measurement of several metabolites, including N-acetyl-aspartate (NAA), an amino acid exclusively synthesized in the mitochondria of neurons, and glutamate, an amino acid involved in excitatory neurotransmission and...

  • Classification of schizophrenia patients based on resting-state functional network connectivity. Mohammad R. Arbabshirani; Kiehl, Kent A.; Pearlson, Godfrey D.; Calhoun, Vince D. // Frontiers in Neuroscience;Jul2013, Vol. 7, p1 

    There is a growing interest in automatic classification of mental disorders based on neuroimaging data. Small training data sets (subjects) and very large amount of high dimensional data make it a challenging task to design robust and accurate classifiers for heterogeneous disorders such as...

  • Magnetic resonance imaging findings in schizophrenia and atypical psychoses. Hayashi, T.; Hotta, N.; Andoh, T.; Mori, M.; Fukatsu, N.; Suga, H. // Journal of Neural Transmission;Jun2001, Vol. 108 Issue 6, p695 

    Summary. The differences among MRI findings were studied in schizophrenic psychoses. The schizophrenics and atypical psychotics had significant reductions in bilateral hippocampal volumes compared to controls, but the two patient groups did not differ from each other. As for ventricle volume,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics